PHP
PLSE icon

Parkman Healthcare Partners’s Pulse Biosciences PLSE Stock Holding History

Parkman Healthcare Partners’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,125
Closed -$1.08M – 96
2026
Q1 		$1.08M Buy
+50,125
New +$925K 0.11% 83

Other funds holding PLSE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Parkman Healthcare Partners's PLSE Position: Q2 2026 in Review

Parkman Healthcare Partners sold out of Pulse Biosciences (PLSE) in Q2 2026, closing a stake of 50,125 shares — an estimated $1.08M sold.

Parkman Healthcare Partners first reported a position in PLSE in Q1 2026 and held it in 1 quarter. The position peaked at $1.08M in Q1 2026. 106 funds tracked by Wall St. Rank hold PLSE as of Q2 2026.

  • Parkman Healthcare Partners reported no remaining Pulse Biosciences position as of Q2 2026 after selling out during the quarter.
  • Parkman Healthcare Partners sold 50,125 Pulse Biosciences shares in Q2 2026, an estimated $1.08M.
  • Parkman Healthcare Partners first reported a position in Pulse Biosciences in Q1 2026 and held it in 1 quarter.
  • Parkman Healthcare Partners's Pulse Biosciences position peaked at $1.08M in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Pulse Biosciences as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.